Angelman syndrome (AS) is a genetic disorder characterized by intellectual disability, seizures, and a characteristic behavioral phenotype. It is caused by the loss of function of the maternally inherited UBE3A gene on chromosome 15q11-q13. The disorder is named after British pediatrician Harry Angelman who first described it in 1965.
Genetic Origin
Angelman syndrome is caused by the loss of function of the maternally inherited UBE3A gene on chromosome 15q11-q13. This gene encodes an E3 ubiquitin ligase, which is essential for proper development of neurons in the brain. When the UBE3A gene is mutated or deleted, the resulting protein is not functional, which leads to the neurological and behavioral features of AS.
Diagnosis
Angelman syndrome is typically diagnosed based on clinical criteria, which include intellectual disability, seizures, ataxia, and a characteristic facial appearance. However, molecular testing is available to confirm the diagnosis. Genetic tests such as chromosomal microarray and targeted genetic sequencing can be used to detect mutations or deletions in the UBE3A gene.
Treatment
Currently, there is no cure for Angelman syndrome. Treatment is focused on managing the symptoms of the disorder. This may include medications to control seizures, physical therapy to improve mobility, and speech therapy to help with communication. Other treatments such as nutritional support, occupational therapy, and behavioral interventions may also be helpful.